Posted on

Airway Therapeutics, LLC was created in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center (CCHMC), and has extensive expertise in protein development for applications in the lungs and pediatrics. The company’s first-to-market indication is the development of recombinant human surfactant protein-D (rhSP-D, AT-100) as a replacement protein therapy for the prevention of bronchopulmonary dysplasia (BPD) in premature infants. AT-100 is in advanced preclinical stage development and has received orphan designation for prevention of BPD in both the US and the EU.